263 related articles for article (PubMed ID: 24222331)
1. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden.
Turesson I; Kovalchik SA; Pfeiffer RM; Kristinsson SY; Goldin LR; Drayson MT; Landgren O
Blood; 2014 Jan; 123(3):338-45. PubMed ID: 24222331
[TBL] [Abstract][Full Text] [Related]
2. Determining the significance of MGUS.
Merlini G
Blood; 2014 Jan; 123(3):305-7. PubMed ID: 24434993
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.
Kyle RA; Larson DR; Therneau TM; Dispenzieri A; Kumar S; Cerhan JR; Rajkumar SV
N Engl J Med; 2018 Jan; 378(3):241-249. PubMed ID: 29342381
[TBL] [Abstract][Full Text] [Related]
5. [Monoclonal gammopathy of undetermined significance and evolution to myeloma: Experience in 153 patients].
López Gómez JM; Sacristán Enciso B; Fernández-Cavada Pollo MJ; Bueno García V; Gómez Vera S
Semergen; 2021 Oct; 47(7):441-447. PubMed ID: 34479794
[TBL] [Abstract][Full Text] [Related]
6. A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance.
Sandecká V; Hájek R; Pour L; Špička I; Ščudla V; Gregora E; Radocha J; Walterová L; Kessler P; Zahradová L; Adamová D; Valentova K; Vonke I; Obernauerová J; Starostka D; Wróbel M; Brožová L; Jarkovský J; Mikulášová A; Říhová L; Ševčíková S; Straub J; Minařík J; Adam Z; Krejčí M; Král Z; Maisnar V;
Eur J Haematol; 2017 Jul; 99(1):80-90. PubMed ID: 28384387
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.
Dispenzieri A; Katzmann JA; Kyle RA; Larson DR; Melton LJ; Colby CL; Therneau TM; Clark R; Kumar SK; Bradwell A; Fonseca R; Jelinek DF; Rajkumar SV
Lancet; 2010 May; 375(9727):1721-8. PubMed ID: 20472173
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
9. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
10. Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age.
Cherry BM; Costello R; Zingone A; Burris J; Korde N; Manasanch E; Kwok M; Annunziata C; Roschewski MJ; Engels EA; Landgren O
Am J Hematol; 2013 Feb; 88(2):89-92. PubMed ID: 23169485
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
12. Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota.
Kleinstern G; Larson DR; Allmer C; Norman AD; Muntifering G; Sinnwell J; Visram A; Rajkumar V; Dispenzieri A; Kyle RA; Slager SL; Kumar S; Vachon CM
Blood Cancer J; 2022 Apr; 12(4):67. PubMed ID: 35440099
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
[TBL] [Abstract][Full Text] [Related]
14. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
Chang SH; Gumbel J; Luo S; Thomas TS; Sanfilippo KM; Luo J; Colditz GA; Carson KR
Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2055-2061. PubMed ID: 31501149
[TBL] [Abstract][Full Text] [Related]
15. Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients.
Weiss BM; Minter A; Abadie J; Howard R; Ascencao J; Schechter GP; Kuehl M; Landgren O
Am J Hematol; 2011 Jun; 86(6):475-8. PubMed ID: 21544856
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma].
Ščudla V; Petrová P; Pika T; Lochman P; Minařík J; Bačovský J; Srovnalík K
Cas Lek Cesk; 2015; 154(4):181-8. PubMed ID: 26357861
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma.
Gran C; Liwing J; Wagner AK; Verhoek A; Gezin A; Alici E; Nahi H
Am J Hematol; 2021 Jan; 96(1):23-30. PubMed ID: 32936979
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
Kyle RA; Durie BG; Rajkumar SV; Landgren O; Blade J; Merlini G; Kröger N; Einsele H; Vesole DH; Dimopoulos M; San Miguel J; Avet-Loiseau H; Hajek R; Chen WM; Anderson KC; Ludwig H; Sonneveld P; Pavlovsky S; Palumbo A; Richardson PG; Barlogie B; Greipp P; Vescio R; Turesson I; Westin J; Boccadoro M;
Leukemia; 2010 Jun; 24(6):1121-7. PubMed ID: 20410922
[TBL] [Abstract][Full Text] [Related]
20. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Cairns DA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
Lancet Haematol; 2017 Dec; 4(12):e584-e594. PubMed ID: 29146225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
